WU Lin, FU Rui. Efficacy of Dacomitinib Versus Gefitinib as First-Line Treatment for Patients with EGFR Mutation Positive Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(4): 212-216. DOI: 10.12019/j.issn.1671-5144.2019.04.004
|
Citation:
|
WU Lin, FU Rui. Efficacy of Dacomitinib Versus Gefitinib as First-Line Treatment for Patients with EGFR Mutation Positive Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(4): 212-216. DOI: 10.12019/j.issn.1671-5144.2019.04.004
|
WU Lin, FU Rui. Efficacy of Dacomitinib Versus Gefitinib as First-Line Treatment for Patients with EGFR Mutation Positive Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(4): 212-216. DOI: 10.12019/j.issn.1671-5144.2019.04.004
|
Citation:
|
WU Lin, FU Rui. Efficacy of Dacomitinib Versus Gefitinib as First-Line Treatment for Patients with EGFR Mutation Positive Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(4): 212-216. DOI: 10.12019/j.issn.1671-5144.2019.04.004
|
DownLoad: